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Photocatalytic degradation of ofloxacin and
evaluation of the residual antimicrobial activity
M. S. Peres, M. G. Maniero and J. R. Guimarães*
Ofloxacin is an antimicrobial agent frequently found in significant concentrations in wastewater and
surface water. Its continuous introduction into the environment is a potential risk to non-target organisms
or to human health. In this study, ofloxacin degradation by UV/TiO2 and UV/TiO2/H2O2, antimicrobial
activity (E. coli) of samples subjected to these processes, and by-products formed were evaluated.
For UV/TiO2, the degradation efficiency was 89.3% in 60 min of reaction when 128 mg L
−1 TiO2 were
used. The addition of 1.68 mmol L−1 hydrogen peroxide increased degradation to 97.8%. For UV/TiO2,
increasing the catalyst concentration from 4 to 128 mg L−1 led to an increase in degradation efficiency.
For both processes, the antimicrobial activity was considerably reduced throughout the reaction time.
The structures of two by-products are presented: m/z 291 (9-fluoro-3-methyl-10-(methyleneamino)-
7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid) and m/z 157 ((Z)-2-formyl-
3-((2-oxoethyl)imino)propanoic acid).
1. Introduction
The concentration of pharmaceuticals in the aquatic environ-
ment is low, ranging from ng L−1 to µg L−1. However, in the
long term continuous introduction of pharmaceuticals into
water may be a risk to aquatic and terrestrial organisms, so
significant efforts must be made to develop effective means
of minimizing exposure of environmental microbiota to anti-
microbial compounds.
Ofloxacin (OFX) is an antimicrobial agent of the fluoro-
quinolone family. Fluoroquinolones are not completely metabolized
by the human body. From 20 to 80% of fluoroquinolones that
are ingested are excreted in a pharmacologically active form.1
For this reason, fluoroquinolones affect domestic sewage.
Residual concentrations of fluoroquinolones and of other anti-
microbials present in wastewater can be harmful to organisms
in the water that receives them.2 Bacteria exposed to antimicro-
bial residues present in environmental matrices may undergo
alterations in their genes, resulting in microorganisms that are
resistant to the compound. More powerful drugs must be used
in the treatment of diseases because of drug-resistant bacteria.
So, it is very important to use treatment technologies that
are capable of removing the residual antimicrobial activity of
these compounds.
Significant concentrations of ofloxacin have been detected
in surface water (10–535 ng L−1), municipal wastewater treat-
ment plant effluent (53–1800 ng L−1), and hospital wastewater
(25 000–35 000 ng L−1).3,4 Studies have shown that advanced
oxidation processes (AOPs) are effective in degrading ofloxacin
in aqueous solutions. Michael et al.,5 Hapeshi et al.,4 Prieto-
Rodriguez et al.,6 and Vasquez et al.7 used the photocatalytic
process with UV/TiO2. Despite the importance of minimizing
bacterial resistance, most studies on antimicrobial degradation
by AOPs evaluate only the removal of the parent compound.
Biological effects that can be induced by partial oxidation and/
or degradation of by-products are rarely discussed.
Among the AOPs available, photocatalysis using titanium
dioxide (TiO2) as a catalyst is able to achieve complete oxi-
dation of organic pollutants by generating hydroxyl radicals
when the catalyst is exposed to ultraviolet radiation.8 It should
be noted that the adsorption of contaminants by TiO2 is key to
this AOP, since the compound needs to be adsorbed on the
surface of the catalyst for the oxidation reaction to take place.
The efficiency of the adsorption of the compound on the semi-
conductor varies. This depends on the pollutant, adsorbent
concentration, pH, and matrix complexity.
The objectives of the present study were to assess the degra-
dation of ofloxacin in aqueous solutions by photocatalysis
with TiO2 in suspension, to investigate the influence of adding
hydrogen peroxide to the process, to evaluate the residual
antimicrobial activity of solutions subjected to photocatalytic
processes, and to identify by-products formed during the
processes.
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2. Materials and methods
2.1. Chemicals
The following chemicals were used in the assays: ofloxacin
(99.8% w/w, C18H20FN3O4, 361.368 g mol
−1) and oxalic acid
(99.5% w/w) from Sigma–Aldrich (St. Louis, USA); hydrogen
peroxide (30% w/w), H2SO4 (97% v/v), and NaOH (97% w/w)
from Synth (Diadema, Brazil); methanol (HPLC grade) and
BaCl2·2H2O (99% w/w) from J.T. Baker (Edo, Mexico); H3PO4
(85% v/v) and KH2PO4 (98% w/w) from Nuclear (São Paulo,
Brazil); KOH (85% w/w) from Ecibra (São Paulo, Brazil); and
NH4VO3 (99% w/w) from Honeywell Riedel-de Haën (Seelze,
Germany). TiO2 was obtained from Degussa (Frankfurt,
Germany). Mueller–Hinton broth cultures and Mueller–Hinton
Agar were purchased from Himidia (Mumbai, India). The ultra-
pure water used in the study was produced using a Milli-Q
Academic water purification system (Millipore).
2.2. Stock solution
Ofloxacin stock solution (500 mg L−1) was prepared in metha-
nol, stored at 4 °C, and protected from light. The ofloxacin
working solutions (500 µg L−1, pH 6) were prepared by diluting
the stock solution in 1 L of ultrapure water.
2.3. Experimental setup
The degradation assays were carried out in a 38.5 cm-long,
3.5 cm-inner-diameter borosilicate glass reactor (190 mL). A
low pressure mercury lamp (15 W, λmax = 254 nm and 2.4 cm
internal diameter) was inserted in the centre of the tube. The
lamp was in direct contact with the solution. The system was
operated in batches with recirculation with a flow rate of
100 mL min−1. The experimental system was made up of a
magnetic stirrer, a 1000 mL reservoir, a peristaltic pump to re-
circulate the solution, and a photochemical reactor. A similar
experimental system was utilized by da Silva et al.9 and Gua-
dagnini et al.10 The irradiance was 6.95 mW cm−2, measured
using a Cole Parmer (VLX 3W model) radiometer calibrated at
254 nm.
The reaction time varied from 0 to 60 min. The TiO2 catalyst
(Degussa P-25) was kept in suspension by stirring; the concen-
tration varied from 4 to 128 mg L−1. After the degradation
assays, TiO2 was removed from the solution by filtration with a
GF 51-B glass membrane. In the UV/TiO2/H2O2 experiments,
1.68 mmol L−1 H2O2 was added. Consumption of hydrogen
peroxide was measured using the method described by
Nogueira et al.11
Ofloxacin adsorption on the catalyst was evaluated by
adding TiO2 at concentrations ranging from 4 to 128 mg L
−1 to
1 L of ofloxacin working solution at pH 3, 6, and 10. The
contact time varied from 0 to 90 min. Equilibrium was reached
after 30 minutes of testing, so the photocatalysis assays were
carried out after ofloxacin solutions had been placed in
contact with the catalyst for 30 minutes. TiO2 was removed by
filtration with a GF 51-B glass membrane. The aqueous solu-
tion with the remaining ofloxacin was then concentrated by
solid phase extraction (SPE), and the extract was quantified by
high performance liquid chromatography (HPLC) analysis.
2.4. Analytical methods
2.4.1. High performance liquid chromatography. Degra-
dation of ofloxacin was assessed by HPLC with UV detection
(298 nm). Before quantification, samples were concentrated
using SPE with Waters OASIS HLB cartridges (500 mg/6 mL)
conditioned with methanol (6.0 mL) and water (6.0 mL). One
litre of the sample was percolated through the cartridges at a
flow rate of 10 mL min−1. Analytes were eluted with methanol
(4.0 mL). The extract was filtered (0.22 μm membrane filters)
before HPLC analyses. Recovery ranged from 96.3 to 107% for
samples containing 10–500 µg L−1 ofloxacin.
The HPLC consisted of a Waters Model 510 delivery system,
a Rheodyne Model 7725 injector with a 20 µL sample loop,
and a tunable Waters Model 486 absorbance detector. Data
were acquired using a Waters 746 Data Module integrator.
Quantification was performed at 298 nm. The analytical
column was a Waters X-Bridge® RP18 (250 mm × 4.6 mm I.D.,
5 µm). The flow rate was 1.0 mL min−1. The mobile phase con-
sisted of methanol: 0.01 mol L−1 oxalic acid (35 : 65 v/v). LOD
was 0.04 µg L−1 and LOQ was 0.2 µg L−1, considering a concen-
tration factor of 250 times.
2.4.2. Mass spectrometry. To determine the by-products
generated by the application of advanced oxidation processes,
a Micro Four model (Waters, USA) triple quadrupole mass
spectrometer was used with an electrospray ionization source
(ESI) operated in positive mode. Ofloxacin solutions of 5 mg
L−1 were used in order to avoid analyte loss during the SPE
process. OFX solution aliquots (1 mL) were collected at 5, 10,
15, 30, and 60 min. Spectra were acquired between m/z 100
and 600. The typical operating conditions were as follows:
cone energy (25 V), capillary energy (3000 V), resolution (0.75
Da), cone gas flow (10 L h−1), desolvation gas flow (1000 L
h−1), extraction cone energy (3 V), desolvation temperature
(500 °C), and infusion flow (20 µL min−1). Data were acquired
using the MassLynx® software.
2.5. Antimicrobial activity assay
Antimicrobial activity was evaluated quantitatively. It used an
E. coli K12 culture with a population density of 1.0 × 106 CFU
mL−1. The assays followed the procedures by Rodrigues-Silva
et al.,12 with some modifications, using a 96-well microtiter
plate. An aliquot of 350 µL of standard and degraded samples
at pH 6 was added to the first well of each row. Then an
18-member serial dilution (1.4-fold) was performed by trans-
ferring 250 µL from the first well to the second well. This pro-
cedure was repeated until 17th well. The last well (i.e., the 18th
well) contained only the phosphate buffer solution. The anti-
microbial activities of the ofloxacin standard, the initial
samples (t = 0 min), and degraded samples (t = 15, 30, 45,
60 min) were quantified in duplicate. After the serial dilution,
all of the wells of the 96-well plate were inoculated with 100 µL
of E. coli culture solution. Subsequently, the plate was covered,
sealed and incubated on a shaker (Marconi model MA-420) for
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8 h at 37 °C. After this period, the absorbance of each sample
well was measured at 630 nm using a Multiskan MS microplate
reader (Labsystems). Values for growth inhibition (%), I, were
obtained using eqn (1)
Ið%Þ ¼ A0  A
A0
 100% ð1Þ
in which A0 is the absorbance of the E. coli culture incu-
bated with phosphate buffer, equivalent to non-inhibited
growth, and A is the absorbance recorded in each well at
630 nm.
The dose–response curves and the EC50 values of the
degraded and untreated solutions were evaluated using the
Graph-Pad Prism 5.0 software (La Jolla, USA), as in eqn (2)
Ið%Þ ¼ Imin;t þ Imax;t  Imin;t1þ 10ðlog EClogð1=mnÞHÞð Þ ð2Þ
in which log EC is equal to log EC50Control plus log EC50Ratio;
EC50 is the effective dose at which 50% growth inhibition is
achieved; Imax,t represents the maximum growth inhibition;
Imin,t represents the minimum growth inhibition for each
sample; H is the Hill slope.
The residual activity of the samples subjected to the degra-
dation processes was compared with the antimicrobial activity
of the untreated samples (t = 0 min). The effective dose
capable of causing 50% inhibition of bacterial growth (EC50)
was determined by exposing the E. coli culture to ofloxacin
concentrations varying from 250 µg L−1 to 152.4 ng L−1.
Changes in the EC50 values of the samples during the
degradation processes were evaluated by calculating the
potency equivalent value (PEQ), as in eqn (3)
PEQ ¼ EC50;0=EC50;X ð3Þ
in which PEQ is the potency equivalent value, EC50,0 is the
effective dose at which 50% growth inhibition was observed in
the untreated ofloxacin solution, and EC50,X is the EC50 value
calculated for each sample subjected to the degradation
process.
3. Results and discussion
3.1. Adsorption of ofloxacin on the TiO2 surface
The adsorption of ofloxacin on the catalyst did not exceed 30%
for any of the conditions evaluated. These results are consist-
ent with those of Hapeshi et al.4 who verified that 30 min was
sufficient to ensure the maximum adsorption of ofloxacin on
the catalyst surface. This same period was used by Vasquez
et al.7 for photocatalysis assays.
3.2. pH effect
pH is an important parameter that can affect photocatalytic
reactions. In this study the degradation of ofloxacin was evalu-
ated at different pH values (3, 6, and 10), as shown in Fig. 1A.
The efficiency of the photocatalytic process is related to the
surface ionization state of the catalyst,13 as shown in eqn (4)
and (5).
TiOHþHþ $ TiOH2þ ð4Þ
TiOHþ OH $ TiO þH2O ð5Þ
pH changes can influence ofloxacin molecule adsorption
on the catalyst surface, which is decisive for the occurrence of
photocatalytic oxidation reactions. The zero charge point of
TiO2 (Degussa P-25) is at pH 6. Thus, the catalyst surface is
positively charged in acidic medium (pH < 6) and negatively
charged in basic medium (pH > 6).
Ofloxacin is positively charged at pH values lower than the
pKa1 (6.05), negatively charged at pH values above the pKa2
(8.11), and neutral at pH values between pKa1 and pKa2.
4 There-
fore, pH 3 and 10 are not favorable for ofloxacin adsorption on
the catalyst surface, since there is electronic repulsion between
the charges of the compound and the catalyst with the same
Fig. 1 (A) Degradation of ofloxacin by UV/TiO2 (pH 3, 6, and 10). (B)
Degradation of ofloxacin by UV and UV/TiO2 at pH 6; the TiO2 concen-
tration ranging from 4 to 128 mg L−1.
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sign. At pH 6, both the catalyst molecule and the drug are in
their neutral forms, and no repulsion occurs between them.
When the catalyst concentration was increased from 8 to
32 mg L−1, the effect that pH has on the drug degradation
efficiency was more pronounced, that is there was a more
notable difference between the results obtained at pH 6 than
those at pH 3 and 10. Photocatalysis degradation efficiencies
at pH 3 and 10 were lower than those obtained for the same
process at pH 6. This was probably due to the charge-repulsion
phenomenon, which is not favorable to ofloxacin adsorption
on TiO2.
3.3. Ofloxacin degradation
Photocatalysis was effective for ofloxacin degradation (Fig. 1B).
For all concentrations tested, this process was more efficient
than photolysis. An increase in degradation efficiency was
observed when the catalyst concentration was increased from 4
to 128 mg L−1. This correlation between the degradation rate
and the catalyst concentration is due to the large number of
active TiO2 sites available for the photocatalytic reaction.
Concentrations of TiO2 higher than 128 mg L
−1 were not
used because they did not lead to significant gains in drug
degradation efficiency. Very high catalyst concentrations cause
turbidity in the solution, hinder the penetration of incident
UV radiation, and impair the efficiency of the photocatalytic
process.14
The maximum degradation of ofloxacin obtained by the
photolysis process was 51% after 60 min of testing. Using
4 mg L−1 TiO2, the drug degradation efficiency was slightly
better than for photolysis, reaching 56.2% after 60 min. When
8 mg L−1 catalyst was used, degradation increased, reaching
57.4% after 60 min. The application of TiO2 caused a signifi-
cant OFX degradation gain for the TiO2 concentration varying
from 16 to 64 mg L−1. As can be seen in Fig. 1B, after 60 min,
the maximum degradation efficiency was 89.3%, when 128 mg
L−1 catalyst was used.
TiO2 photocatalysis was also used by Michael et al.
5 to
degrade 10 mg L−1 ofloxacin (catalyst concentration of 3 g L−1):
60% degradation was obtained after 120 min of irradiation.
Vasquez et al.7 achieved 100% degradation of a 10 mg L−1 OFX
solution in 30 min using the photocatalyst (1 g L−1 TiO2).
Hapeshi et al.4 achieved 88% degradation of 20 mg L−1 ofloxa-
cin solution in 240 min using UV/TiO2 (250 mg L
−1 TiO2). In a
study carried out by Prieto-Rodriguez et al.,6 a solution of 1.61
× 10−3 mg L−1 OFX underwent a photocatalytic process (20 mg
L−1 TiO2) for 300 min, resulting in approximately 90% degra-
dation. Ofloxacin degradation results obtained in the present
study were similar to those in the literature. This drug can be
efficiently degraded by photocatalysis. However, the vast
majority of existing studies use ofloxacin and TiO2 concen-
trations much higher than those used in this study, that is 500
µg L−1 ofloxacin and 128 mg L−1 TiO2. This reduction in the
levels of the drug and chemicals differentiates the present
study from the others.
3.3.1. Influence of adding hydrogen peroxide. The
addition of hydrogen peroxide to the photocatalytic process
was assessed. According to Chu et al.,15 when small amounts
of hydrogen peroxide are introduced into the UV/TiO2 process,
the degradation efficiency increases because more hydroxyl
radicals are generated by UV/H2O2. Moreover, Hapeshi et al.
4
reported that the use of hydrogen peroxide can result in higher
degradation efficiency because there are more hydroxyl radical
formation reactions, shown in eqn (6) and (7).
H2O2 þ O2• ! HO• þ OH þ O2 ð6Þ
H2O2 þ e ! HO• þ OH ð7Þ
The addition of hydrogen peroxide led to an increase in the
efficiency of the process, especially in the first 15 min of
testing, as can be seen in Fig. 2. Comparing the results
obtained using 8 mg L−1 TiO2, the addition of hydrogen per-
oxide resulted in a gain of about 30% in drug reduction
efficiency, reaching 86.8% after 60 min. When 32 mg L−1 cata-
lyst were used, after 60 minutes, the degradation efficiency
increased from 75.8% to 94.6% when H2O2 was added.
Degradation of 95.6% was obtained by adding hydrogen
peroxide to the UV/TiO2 process, using 64 mg L
−1 TiO2. In the
UV/H2O2 process (1.68 mmol L
−1 H2O2), 25% of ofloxacin
degradation was observed after 15 min. The maximum degra-
dation was 96.8% after 60 min. The addition of the catalyst
(UV/TiO2/H2O2 process, with 1.68 mmol L
−1 H2O2 and 128 mg
L−1 TiO2) raised this result to 65.3% after 15 min of testing.
The best result obtained from this process was 97.8% degra-
dation after 60 min.
3.4. Antimicrobial activity
The EC50 values obtained ranged from 7.89 µg L
−1 to 8.55 µg
L−1. The mean value was 8.22 µg L−1, which was taken to be
the EC50 of ofloxacin.
Dose–response curves illustrate the relationship between
serial dilution and growth inhibition percentage, and they are
shown in Fig. 3. A shift of the dose–response curves to the
Fig. 2 Degradation of ofloxacin by UV/H2O2, UV/TiO2 and UV/TiO2/
H2O2 (1.68 mmol L
−1 H2O2).
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right indicates that the antimicrobial activity of the sample
was reduced. The application of photolysis (Fig. 3A) for 60 min
decreased the antimicrobial activity by 42%. The UV/TiO2
process was efficient at reducing the biological activity. There
was 65% reduction when 8 mg L−1 TiO2 was used (Fig. 3C).
Reduction was 77% when 32 mg L−1 TiO2 was used (figure not
shown). It reached 91% when 128 mg L−1 TiO2 was used
(Fig. 3D). The reaction time was 60 min. UV/TiO2/H2O2
(1.68 mmol L−1 H2O2) was able to decrease the activity by 67%
when 8 mg L−1 TiO2 was applied (Fig. 3E), 93% when 32 mg
L−1 TiO2 was applied (figure not shown), and 96% when
128 mg L−1 TiO2 was applied (Fig. 3F).
Comparing the results for photolysis and UV/TiO2, the
addition of the catalyst is seen to result in a greater reduction
of antimicrobial activity. When 128 mg L−1 TiO2 was used, UV/
TiO2/H2O2 (1.68 mmol L
−1 H2O2) was more efficient than UV/
H2O2 in reducing the biological activity, even when four times
as much oxidant was used (6.77 mmol L−1 H2O2) in the UV/
H2O2 process (Fig. 3B).
The antimicrobial activity of ofloxacin is linked to the pres-
ence of carboxylic and carbonyl groups in the molecule.16
Thus, the reduction in antimicrobial activity could be related
to the reactions that occurred in this domain.
A relationship between degradation efficiency and anti-
microbial activity reduction was observed. Therefore, the degra-
dation processes did not generate by-products with greater
antimicrobial activity than the parent compound. Dodd
et al.,17 Paul et al.,18 and da Silva et al.9 verified that the anti-
microbial activity of some fluoroquinolones decreased after
drug degradation by advanced oxidation processes.
3.5. By-products formed during ofloxacin degradation
Mass spectrometry assays were performed to identify the pro-
ducts generated during the UV/TiO2 process. Fig. 4 shows
mass spectra obtained from the best degradation condition
(128 mg L−1 of TiO2). A decrease in the signal intensity of the
original molecule (ofloxacin, m/z 362, t = 0 min) was observed
when its degradation by-products appeared. Possible struc-
tures of some of the degradation by-products (m/z 291 and m/z
157) are shown in Fig. 5.
The intermediate with m/z 291 is generated due to piper-
azine ring oxidation. According to Hapeshi et al.,19 ofloxacin
Fig. 3 Antimicrobial activity of OFX solutions subjected to (A) photolysis, (B) UV/H2O2 (6.77 mmol L
−1 H2O2), (C) UV/TiO2 8 mg L
−1, (D) UV/TiO2
128 mg L−1, (E) UV/TiO2/H2O2 8 mg L
−1 TiO2 and 1.68 mmol L
−1 H2O2, and (F) UV/TiO2/H2O2 128 mg L
−1 TiO2 and 1.68 mmol L
−1 H2O2.
Fig. 4 Mass spectra of the ofloxacin solution subjected to UV/TiO2
(128 mg L−1 of TiO2) at t = 0, 5, 10, 15, 30, and 60 min.
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molecule cleavage (C11H15FN2 loss) can form an intermediate
with m/z 169. The subsequent loss of a methyl group gives rise
to a by-product with m/z 157. The structures of all products
generated could not be identified because hydroxyl radicals do
not attack organic compounds selectively, i.e. the radical can
interact with any region of the target molecule. The analyte’s
chemical structure can hinder the investigation of the inter-
mediates formed.20 It is worth mentioning that to prove the
identity of the intermediates formed, analytical standards
must be acquired. They are not always available,20,21 so they
must be synthesized.
There have been some studies showing that fluoroquino-
lones are susceptible to photochemical transformations by
exposure to ultraviolet radiation.22,23 They offer limited evi-
dence that such processes may diminish the antimicrobial
activity of solutions. According to Shen et al.,24 the core of
the molecular structure of fluoroquinolones is responsible
for drug binding to bacteria DNA. Therefore, it is expected
that the antimicrobial activity of the drug would be reduced
only when this part of the structure is degraded. However,
even if the degradation by-products have an intact quinolone
core, their antimicrobial activity is lower;18 this indi-
cates that changes in auxiliary functional groups can also
decrease the antimicrobial activity. The piperazine ring of
ofloxacin is responsible for providing recognition and binding
the drug to the topoizomerase DNA enzymes of the bacteria.
Therefore, the by-product with m/z 291, which has structural
fragmentation, has lower affinity to the target bacteria. It
has lower antimicrobial activity than the parent compound.25
According to Shen et al.,24 fluoroquinolones require the
carboxyl group (–COOH) for activity; therefore, the proposed
by-product with m/z 157 has no antimicrobial activity.
Paul et al.18 showed that there was a significant decrease
(over 90%) of the antimicrobial activity of ciprofloxacin
solutions undergoing peroxidation assisted by UV radiation
(UV/H2O2) and photocatalysis.
Vasquez et al.7 suggested that there are two main routes for
the generation of ofloxacin by-products by photolytic and
photocatalytic reactions: dealkylation of the piperazine ring
and decarboxylation (removal of the carboxyl group, –COOH).
Studies have shown that the principal photolytic reactions that
occur are that fluoroquinolones lose fluoride (F−), followed by
decarboxylation.22,26
The loss of fluoride in aqueous neutral solutions of fluoro-
quinolones does not occur under acidic conditions or for
fluoroquinolones with electron donating groups, which is the
case for ofloxacin. The insertion of an electron donor substitu-
ent at C-8 (alkoxy) stabilizes the molecule and makes the fluor-
ide exit reaction inefficient.27 Under these conditions, the
alkylamine side chain is partially degraded, leaving the fluor-
ine attached to an intact heterocyclic chain.22
Small molecules such as water and carbon dioxide are
eliminated by ofloxacin when this compound is subjected to
photolysis and TiO2 photocatalysis, as reported by Calza
et al.28 Subsequent attacks of hydroxyl radicals can lead to the
formation of bi- or tri-hydroxylated products or dimerization
of the ofloxacin molecule, resulting in by-products with m/z
greater than the parent molecule.19 In this study, by-products
with a higher molecular mass than ofloxacin were also formed.
4. Conclusions
The photocatalytic process (UV/TiO2) was highly effective in
ofloxacin degradation: 89.3% was reduced after 60 min. The
addition of hydrogen peroxide (UV/TiO2/H2O2) resulted in
more drug degradation (97.8%) and greater antimicrobial
activity reduction. With the decrease of ofloxacin concen-
tration, the antimicrobial activity also decreased, showing that
there is a relationship between degradation and antimicrobial
activity reduction.
These photocatalytic processes can be applied in the treat-
ment of effluents containing ofloxacin, reducing the concen-
tration of this compound and the solution antimicrobial
activity. These advanced oxidation processes are new options
for the treatment of effluents containing this class of compounds.
They contribute to the reduction of environmental impacts
when these compounds are disposed of in bodies of water.
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